Skip to main content
SpringerLink
Log in

An unusual case of a generalised cutaneous drug reaction to liraglutide

  • Residents’ Corner
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–40.

    Article  CAS  Google Scholar 

  2. Buse J, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exanatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.

    Article  CAS  Google Scholar 

  3. Jacobsen L, Flint A, Olsen A, et al. Liraglutide in type 2 diabetes mellitus: clinical pharmocokinetics and pharmocodynamics. Clin Pharmacokinet 2016; 55: 657–62.

    Article  CAS  Google Scholar 

  4. Garber A, Henry R, Garcia-Hernandez P, et al. Lirgalutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double blind, parallel-treatment trial. Lancet 2009; 373: 473–81.

    Article  CAS  Google Scholar 

  5. Shamriz O, NaserEddin A, Mosenzon O, et al. Allergic reaction to exanatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide receptor agonists. Diabetes Care 2019; 42: e141–2.

    Article  Google Scholar 

  6. Besemer F, Verschoor A, Diamant M, et al. Vesiculopustular dermatosis: an uncommon side effect of liraglutide? J Diabetes Complications 2012; 26: 458–9.

    Article  Google Scholar 

  7. Idorn T, Knop F, https://care.diabetesjoumals.Org/content/39/2/206.full-text.pdf — aff-2Morten B, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care 2016; 39: 206–13.

    Article  CAS  Google Scholar 

  8. Al-Badri M, Azar S. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab 2014; 5: 34–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Churchill Hospital, Oxford, UK

    Louise Bovijn & Sanju Arianayagam

  2. Department of Cellular Pathology, John Radcliffe Hospital, Oxford, UK

    Ruth Asher

Authors
  1. Louise Bovijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanju Arianayagam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruth Asher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanju Arianayagam.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bovijn, L., Arianayagam, S. & Asher, R. An unusual case of a generalised cutaneous drug reaction to liraglutide. Eur J Dermatol 29, 675–677 (2019). https://doi.org/10.1684/ejd.2019.3691

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2019.3691

Search

Navigation